Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Green Cross Health And 2 Other Promising Penny Stocks To Consider

In This Article:

As global markets react to recent political shifts and economic policies, investors are witnessing record highs in major benchmarks like the S&P 500 and Dow Jones Industrial Average. Amidst this backdrop, penny stocks—often representing smaller or emerging companies—continue to capture interest due to their potential for growth at lower price points. While the term "penny stock" might seem outdated, these investments can offer significant opportunities when focused on companies with strong financials and promising growth prospects.

Top 10 Penny Stocks

Name

Share Price

Market Cap

Financial Health Rating

BP Plastics Holding Bhd (KLSE:BPPLAS)

MYR1.22

MYR343.4M

★★★★★★

Rexit Berhad (KLSE:REXIT)

MYR0.785

MYR135.97M

★★★★★★

DXN Holdings Bhd (KLSE:DXN)

MYR0.475

MYR2.36B

★★★★★★

Lever Style (SEHK:1346)

HK$0.87

HK$545.92M

★★★★★★

ME Group International (LSE:MEGP)

£2.25

£847.72M

★★★★★★

Seafco (SET:SEAFCO)

THB2.04

THB1.67B

★★★★★★

LaserBond (ASX:LBL)

A$0.615

A$71.21M

★★★★★★

Hil Industries Berhad (KLSE:HIL)

MYR0.865

MYR287.13M

★★★★★★

Wellcall Holdings Berhad (KLSE:WELLCAL)

MYR1.53

MYR761.86M

★★★★★★

Embark Early Education (ASX:EVO)

A$0.80

A$140.36M

★★★★☆☆

Click here to see the full list of 5,758 stocks from our Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Green Cross Health

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Green Cross Health Limited is a New Zealand-based company that offers healthcare and advisory services, with a market capitalization of NZ$114.88 million.

Operations: The company generates revenue from two primary segments: Medical Services, which contributes NZ$140.27 million, and Pharmacy Services, accounting for NZ$363.64 million.

Market Cap: NZ$114.88M

Green Cross Health, with a market cap of NZ$114.88 million, faces challenges typical of smaller stocks. The company has experienced negative earnings growth over the past year and five years, with current net profit margins decreasing to 2.4%. Despite these hurdles, its debt situation has improved over time, reducing from a debt-to-equity ratio of 36.7% to 21% in five years. Operating cash flow effectively covers its debt obligations at 131.5%, and interest payments are well-covered by EBIT at 3.3 times coverage. Additionally, the management team and board are seasoned with significant tenure averages of 6.3 and 12.7 years respectively.

NZSE:GXH Financial Position Analysis as at Nov 2024
NZSE:GXH Financial Position Analysis as at Nov 2024

Sunsweet

Simply Wall St Financial Health Rating: ★★★★☆☆